Emulate Stock

emulatebio.comHealthcareFounded: 2014Funding to Date: $202.31MM

Emulate is a biotechnology company developing advanced in vitro models for understanding how diseases, medicines, chemicals, and foods affect human health.

Register for Details

For more details on financing and valuation for Emulate, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Emulate.

Register Today

Team

Management Team

Geraldine Hamilton Ph.D
Chief Scientific Officer & President
Lewis Rowe
Chief Strategist
Daniel Levner Ph.D
Co-Founder & Chief Technology Officer
Harry Dhaliwal
Chief Financial Officer
David Coon
Chief Executive Officer
Donald Ingber Ph.D
Scientific Founder & Chair of the Scientific Advisory Board

Board Members

Eric Moessinger
Sharon Kedar
Aaron VanDevender Ph.D
Founders Fund
Frank Witney Ph.D
Donald Ingber Ph.D
Shlomo Melmed

Other companies like Emulate in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$400.53MM
Sector
Last Round Est. Valuation
$4.26B
Sector
 
 
Sector
Last Round Est. Valuation
$1.08B
Sector
 
 

News

Emulate’s plan is to invest more heavily in R&D, and create specific organ-on-a-chip applications that they’ve homed in on through conversations with drug companies. So far, Emulate counts 21 major drug companies, including Genentech andJohnson & Johnson as customers.
Emulate has secured a $36 million Series C financing round led by Founders Fund for commercialization of the Human Emulation System™.
Emulate, which creates living products for understanding how diseases, medicines, chemicals, and foods affect human health, raised $36m